Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Financial Bull 3X Shares ETF
FAS
US Stock MarketDetailed Quotes
NextCure (NXTC)
- 9.360
- +0.150+1.63%
Close May 1 16:00 ET
- 9.360
- 0.0000.00%
Post 20:01 ET
33.77MMarket Cap-0.48P/E (TTM)
9.980High9.280Low90.08KVolume9.320Open9.210Prev Close880.22KTurnover3.96%Turnover RatioLossP/E (Static)3.61MShares15.74052wk High0.97P/B21.32MFloat Cap4.09452wk Low--Dividend TTM2.28MShs Float1308.000Historical High--Div Yield TTM7.60%Range %2.688Historical Low9.771Avg Price1Lot Size
NXTC Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
NXTC Orderflow
Unit: --
NXTC Orderflow Trend
IntradayDayWeekMonth
No Data
NextCure (NXTC) News
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
NextCure And Simcere Zaiming Announce Phase 1 Data For SIM0505 In Treatment Of Solid Tumors Will Be Presented At ASCO 2026
NextCure's SIM0505 Receives FDA Fast Track For Platinum-Resistant Ovarian Cancer, Phase 1 Data To Be Presented At ASCO 2026
Express News | NextCure Receives Fast Track Designation for Sim0505 (Cdh6 ADC) in Ovarian Cancer
12 Health Care Stocks Moving In Monday's After-Market Session
NextCure (NXTC) Stock Forum
$NextCure (NXTC.US)$
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
by Globe Newswire
Follow
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC)
Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
by Globe Newswire
Follow
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC)
Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026
$NextCure (NXTC.US)$ 21.5m bought at 8.52, dont get scammed
$NextCure (NXTC.US)$
yep right now! my magical indicator indicated.
yep right now! my magical indicator indicated.
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)